Pepgen Inc PEPG

$3.83 -0.05 (-1.29%)

Valuation

Market cap
268,733,000
Revenue TTM
$0
Net income TTM
$-89,660,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,396,400
Avg volume
3,855,128
Day's range
$3.73 – $4.21
Shares out
69,261,000
Stochastic %K
37%
Beta
2.02
Analysts
Strong Buy
Price target
$13.75

Price

Company profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystr...

Show more

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 797 0979
Website
https://www.pepgen.com
Address
321 Harrison Avenue, 8th Floor, Boston, United States

Latest news

No headlines yet.